

## Supplementary Data

Supplementary Table 1 – Baseline concomitant diseases and lipidaemia (FAS-M12; n=721)

Characteristic	FAS-M12	N
<b>Concomitant diseases</b>		
Vascular disorders, n [%]	536 [74.3]	721
Nervous system disorders, n [%]	236 [32.7]	721
Renal and urinary disorders, n [%]	69 [9.6]	721
Eye disorders, n [%]	21 [2.9]	721
Cardiac disorders, n [%]	120 [16.6]	721
Endocrine disorders, n [%]	54 [7.5]	721
Metabolism and nutrition disorders, n [%]	178 [24.7]	721
<b>Lipidaemia</b>		
Triglycerides [mg/dL]	220.3±104.0	466
Total cholesterol [mg/dL]	197.3±45.1	510
HDL cholesterol [mg/dL]	46.9±20.6	460
LDL cholesterol [mg/dL]	118.2±37.6	469

Data shown as mean ± standard deviation, if not otherwise specified; FAS-M12, full analysis set of patients with month 12 data available


## Supplementary Data

Supplementary Table 2 – Four-point SMBG blood glucose profiles at baseline and changes to month 6 and month 12 after initiation of Gla-300 (FAS-M12; n=721)


Timepoint	Baseline		Change to month 6		P value	Change to month 12		P value
	mean±SD	N	mean±SD	N		mean±SD	N	
Morning preprandial [mg/dL]	176.0±48.5	107	-40.4±54.4	72	<0.0001	-47.8±43.5	56	<0.0001
Morning 2 h postprandial [mg/dL]	213.0±62.6	93	-56.1±63.3	61	<0.0001	-46.4±50.6	51	<0.0001
Lunch 2 h postprandial [mg/dL]	191.7±51.4	91	-48.7±46.9	55	<0.0001	-33.2±56.9	43	0.0004
Dinner 2 h postprandial [mg/dL]	186.3±46.5	96	-38.0±54.6	61	<0.0001	-34.3±33.6	51	<0.0001

SMBG, self-measured blood glucose; FAS-M12, full analysis set of patients with month 12 data available; SD, standard deviation; Gla-300, insulin glargine 300 U/mL


Supplementary Data



Supplementary Figure 1 – Most often used combinations of oral antidiabetic drugs at baseline (A) and after 12 months of Gla-300 treatment (B) (FAS-M12; n=721); denominator for the percentages is the number of patients in the analysis set, i. e. percentage of patients including “unknown/missing data”; Others, other combinations or unknown; DPP-4i, dipeptidyl peptidase-4 inhibitor; FAS-M12, full analysis set of patients with month 12 data available; Gla-300, insulin glargine 300 U/mL; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, sulfonylurea




Patients with at least one non-insulin antidiabetic drug prescribed n=689 (95.5%); Total number of OAD prescribed n=1,111



Patients with at least one non-insulin antidiabetic drug prescribed n=664 (92.1%); Total number of OAD prescribed n=1,054


Supplementary Figure 2 – Most often prescribed non-insulin antidiabetic drugs and fix ratio drug combinations at baseline (A) and after 12 months of Gla-300 treatment (B) (FAS-M12; n=721); AGI, alpha glucosidase inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; FAS-M12, full analysis set of patients with month 12 data available; Gla-300, insulin glargine 300 U/mL; GLP-1 RA, glucagon-like peptide-1 receptor agonist; Met, metformin; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, sulfonylurea, TZD, tiazolidinedione

Supplementary Data




Supplementary Figure 3A – Time to individualized HbA<sub>1c</sub> or FPG target achievement after initiation of BOT with insulin glargine 300 U/mL; brown: median time to target achievement; blue: Kaplan-Meier estimate for target achievement after 6 and 12 months, respectively; FPG target, fasting blood glucose  $\leq 110$  mg/dL ( $\leq 6.1$  mmol/L); BOT, basal insulin supported oral therapy

Supplementary Data




Supplementary Figure 3B – Duration of individualized HbA<sub>1c</sub> or FPG target achievement under BOT with insulin glargine 300 U/mL; brown: median time on target; blue: Kaplan-Meier estimate for further duration on target after 6 months; FPG target, fasting blood glucose  $\leq 110$  mg/dL ( $\leq 6.1$  mmol/L); BOT, basal insulin supported oral therapy

Supplementary Data



Supplementary Figure 4A – Time to individualized HbA<sub>1c</sub> target achievement after initiation of BOT with insulin glargine 300 U/mL; brown: median time to target achievement; blue: Kaplan-Meier estimate for target achievement after 6 and 12 months, respectively; BOT, basal insulin supported oral therapy

Supplementary Data



Supplementary Figure 4B – Duration of individualized HbA<sub>1c</sub> target achievement under BOT with insulin glargine 300 U/mL; brown: median time on target; blue: Kaplan-Meier estimate for further duration on target after 6 months; BOT, basal insulin supported oral therapy